HRP20171807T1 - Spojevi policikličkog karbamoilpiridona i njihova uporaba za liječenje hiv infekcija - Google Patents
Spojevi policikličkog karbamoilpiridona i njihova uporaba za liječenje hiv infekcija Download PDFInfo
- Publication number
- HRP20171807T1 HRP20171807T1 HRP20171807TT HRP20171807T HRP20171807T1 HR P20171807 T1 HRP20171807 T1 HR P20171807T1 HR P20171807T T HRP20171807T T HR P20171807TT HR P20171807 T HRP20171807 T HR P20171807T HR P20171807 T1 HRP20171807 T1 HR P20171807T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- compound according
- hydrogen
- alkyl
- following formula
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title claims 4
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- -1 2,3-difluorophenyl Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Claims (14)
1. Spoj koji ima slijedeću Formulu (I):
[image]
ili stereoizomer ili njegova farmaceutski prihvatljiva sol,
naznačen time da:
Y1 i Y2 su svaki, neovisno, vodik, C1-3alkil ili C1-3haloalkil;
R1 je fenil supstituiran s jednim do tri halogena;
X je -CHR2-;
W je veza ili -CHR3-;
Z je veza ili -CHR4-;
R2, R3, i R4 su svaki, neovisno, vodik ili C1-3alkil;
R5 je vodik, C1-3alkil ili C1-3haloalkil;
L je -C(Ra)2-, -C(Ra)2C(Ra)2- ili -C(Ra)2C(Ra)2C(Ra)2-; i
svaki Ra je, neovisno, vodik, halo, hidroksi ili C1-4alkil.
2. Spoj prema zahtjevu 1 koji ima slijedeću Formulu (I-A):
[image]
ili stereoizomer ili njegova farmaceutski prihvatljiva sol,
naznačen time da:
Y1 i Y2 su svaki, neovisno, vodik, C1-3alkil ili C1-3haloalkil;
R1 je fenil supstituiran s jednim do tri halogena;
X je -CHR2-;
W je veza ili -CHR3-;
Z je veza ili -CHR4-;
R2, R3, i R4 su svaki, neovisno, vodik ili C1-3alkil;
L je -C(Ra)2-, -C(Ra)2C(Ra)2- ili -C(Ra)2C(Ra)2C(Ra)2-; i
svaki Ra je, neovisno, vodik, halo, hidroksi ili C1-4alkil.
3. Spoj prema zahtjevu 1 naznačen time da ima slijedeću Formulu (II):
[image]
proizvoljno ima slijedeću Formulu (II-A):
[image]
4. Spoj prema zahtjevu 1 naznačen time da ima slijedeću Formulu (III):
[image]
proizvoljno ima slijedeću Formulu (III-A):
[image]
5. Spoj prema zahtjevu 1 naznačen time da ima slijedeću Formulu (IV):
[image]
proizvoljno ima slijedeću Formulu (IV-A):
[image]
6. Spoj prema bilo kojem od zahtjeva 1-5, naznačen time da je L -C(Ra)2-, ili -C(Ra)2C(Ra)2-, ili -C(Ra)2C(Ra)2C(Ra)2-.
7. Spoj prema bilo kojem od zahtjeva 1-6 naznačen time da svaki Ra je vodik.
8. Spoj prema bilo kojem od zahtjeva 1-7 naznačen time da R1 je supstituiran s
i) jednim halogenom, proizvoljno pri čemu R1 je 4-fluorofenil ili 2-fluorofenil; ili
ii) dva halogena, proizvoljno pri čemu R1 je 2,4-difluorofenil, 2,3-difluorofenil, 2,6-difluorofenil, 3-fluoro-4-klorofenil, 3,4-difluorofenil, 2-fluoro-3-klorofenil, 2-fluoro-4-klorofenil, ili 3,5-difluorofenil, proizvoljno pri čemu R1 je 2,4-difluorofenil; ili
iii) tri halogena, proizvoljno pri čemu R1 je 2,4,6-trifluorofenil li 2,3,4-trifluorofenil, proizvoljno pri čemu R1 je 2,4,6-trifluorofenil.
9. Spoj prema zahtjevu 1 naznačen time da R5 je i) vodik ili C1-3alkil, ili ii) vodik, ili iii) metil.
10. Spoj prema zahtjevu 1 naznačen time da se bira od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
11. Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1-10, ili stereoizomer ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač, sredstvo za raspadanje ili pomoćno sredstvo.
12. Spoj prema bilo kojem od zahtjeva 1-10 ili farmaceutski pripravak prema zahtjevu 14 naznačen time da je za uporabu u postupku liječenja ili sprječavanja HIV infekcije kod ljudi koji imaju HIV infekciju ili imaju rizik od dobivanja infekcije, navedeni postupak obuhvaća davanje čovjeku terapeutski učinkovite količine spoja prema bilo kojem od zahtjeva 1-10 ili farmaceutsko pripravka prema zahtjevu 11.
13. Spoj kao što je opisano prema bilo kojem od zahtjeva 1-10, ili njegova farmaceutski prihvatljiva sol naznačen time da je za uporabu u medicinskoj terapiji.
14. Spoj kao što je opisano prema bilo kojem od zahtjeva 1-10, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu u profilaktičkom ili terapeutskom liječenju HIV infekcije.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361845807P | 2013-07-12 | 2013-07-12 | |
EP14745053.0A EP3019499B1 (en) | 2013-07-12 | 2014-07-11 | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
PCT/US2014/046415 WO2015006733A1 (en) | 2013-07-12 | 2014-07-11 | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171807T1 true HRP20171807T1 (hr) | 2018-01-26 |
Family
ID=51257630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171807TT HRP20171807T1 (hr) | 2013-07-12 | 2017-11-21 | Spojevi policikličkog karbamoilpiridona i njihova uporaba za liječenje hiv infekcija |
Country Status (18)
Country | Link |
---|---|
US (5) | US9458159B2 (hr) |
EP (2) | EP3019499B1 (hr) |
JP (1) | JP6411492B2 (hr) |
AU (3) | AU2014286995B2 (hr) |
CA (1) | CA2918055C (hr) |
CY (1) | CY1119545T1 (hr) |
DK (1) | DK3019499T3 (hr) |
ES (2) | ES2647216T3 (hr) |
HK (2) | HK1246295A1 (hr) |
HR (1) | HRP20171807T1 (hr) |
HU (1) | HUE037343T2 (hr) |
LT (1) | LT3019499T (hr) |
NO (1) | NO2865735T3 (hr) |
PL (1) | PL3019499T3 (hr) |
PT (1) | PT3019499T (hr) |
RS (1) | RS56539B1 (hr) |
SI (2) | SI3252053T1 (hr) |
WO (1) | WO2015006733A1 (hr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102527797B1 (ko) | 2012-12-21 | 2023-05-03 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
CA2916993C (en) * | 2013-07-12 | 2019-01-15 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
NO2865735T3 (hr) | 2013-07-12 | 2018-07-21 | ||
EP3196201B1 (en) | 2014-08-22 | 2021-04-28 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase-inhibiting activity |
CN107108615B (zh) | 2015-03-04 | 2020-11-20 | 吉利德科学公司 | Toll样受体调节性4,6-二氨基-吡啶并[3,2-D]嘧啶化合物 |
AU2016244035B2 (en) * | 2015-04-02 | 2018-11-01 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
MA42818A (fr) | 2015-09-15 | 2018-07-25 | Gilead Sciences Inc | Modulateurs de récepteurs de type toll pour le traitement du vih |
TWI737647B (zh) | 2015-11-09 | 2021-09-01 | 美商基利科學股份有限公司 | 用於治療人類免疫缺乏病毒之治療組合物 |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
EP3507276B1 (en) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
CN110526930B (zh) * | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
WO2019230857A1 (ja) | 2018-05-31 | 2019-12-05 | 塩野義製薬株式会社 | 多環性ピリドン誘導体 |
CR20230571A (es) | 2018-05-31 | 2024-01-22 | Shionogi & Co | DERIVADO POLICÍCLICO DE CARBAMOILPIRIDONA (divisional 2020-0644) |
EP4122537A1 (en) | 2019-03-22 | 2023-01-25 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
US11697652B2 (en) | 2020-02-24 | 2023-07-11 | Gilead Sciences, Inc. | Tetracyclic compounds and uses thereof |
WO2022159387A1 (en) | 2021-01-19 | 2022-07-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE788516A (fr) | 1971-09-10 | 1973-03-07 | Lonza Ag | Procede de fabrication d'esters alcoxyacetylacetiques |
GB1528382A (en) | 1974-12-26 | 1978-10-11 | Teijin Ltd | Cyclopentene diols and acyl esters thereof and processes for their preparation |
DE2658401A1 (de) | 1976-12-23 | 1978-07-06 | Merck Patent Gmbh | Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
US4575694A (en) | 1984-03-05 | 1986-03-11 | Allied Corporation | Coaxial connector |
DE3900736A1 (de) | 1989-01-12 | 1990-07-26 | Hoechst Ag | Positiv arbeitendes strahlungsempfindliches gemisch enthaltend einen mehrfunktionellen (alpha)-diazo-(beta)-ketoester, verfahren zu dessen herstellung und strahlungsempfindliches aufzeichnungsmaterial enthaltend dieses gemisch |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
DE4014649A1 (de) | 1990-05-08 | 1991-11-14 | Hoechst Ag | Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung |
GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
SE9702772D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
AU1403099A (en) | 1997-11-14 | 1999-06-07 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
JP2002529455A (ja) | 1998-11-09 | 2002-09-10 | ジェームズ・ブラック・ファウンデーション・リミテッド | ガストリンおよびコレシストキニン受容体リガンド類 |
GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
DE69939749D1 (de) | 1998-12-25 | 2008-11-27 | Shionogi & Co | Aromatische heterocyclen mit hiv integrase inhibierenden eigenschaften |
AU2001262732A1 (en) | 2000-06-14 | 2001-12-24 | Shionogi And Co., Ltd. | Inhibitor for enzyme having two divalent metal ions as active centers |
CN101513402B (zh) | 2001-08-10 | 2012-03-21 | 盐野义制药株式会社 | 抗病毒药 |
IL160642A0 (en) | 2001-10-03 | 2004-07-25 | Ucb Sa | Pyrrolidinone derivatives |
BRPI0213522C1 (pt) | 2001-10-26 | 2021-05-25 | St Di Ricerche Di Biologia Molecolare P Angeletti S P A | compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto |
EP1452527B1 (en) | 2001-11-13 | 2009-03-04 | Shiseido Co., Ltd. | Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation |
US7109186B2 (en) | 2002-07-09 | 2006-09-19 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
AU2003267098B2 (en) | 2002-09-11 | 2008-11-20 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors |
EP4059923A1 (en) | 2002-11-20 | 2022-09-21 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
US20040224917A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
AU2005211349A1 (en) | 2004-01-30 | 2005-08-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors |
CN101014574A (zh) | 2004-03-09 | 2007-08-08 | 默克公司 | Hiv整合酶抑制剂 |
EP1755586A2 (en) | 2004-04-29 | 2007-02-28 | The Regents of the University of California | Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
WO2005110399A2 (en) | 2004-04-29 | 2005-11-24 | The Regents Of The University Of California | Zinc-binding groups for metalloprotein inhibitors |
WO2005110414A2 (en) | 2004-05-07 | 2005-11-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
US7531554B2 (en) | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
EP2229945A1 (en) | 2004-05-21 | 2010-09-22 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents |
EP1790638B1 (en) | 2004-09-15 | 2013-04-03 | Shionogi Co., Ltd. | Carbamoylpyridone derivative having hiv integrase inhibitory activity |
CA2634499A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
EP1852434B1 (en) | 2005-02-21 | 2011-07-13 | Shionogi Co., Ltd. | Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity |
WO2006116764A1 (en) * | 2005-04-28 | 2006-11-02 | Smithkline Beecham Corporation | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
EP1888581A2 (en) | 2005-05-16 | 2008-02-20 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
CA2616314A1 (en) | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of hiv |
CA2626956A1 (en) | 2005-10-27 | 2007-05-03 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
EP2308490A1 (en) | 2005-12-30 | 2011-04-13 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
JP2009525261A (ja) | 2006-02-01 | 2009-07-09 | 日本たばこ産業株式会社 | レトロウイルス感染症の治療のための、6−(3−クロロ−2−フルオロベンジル)−1−[(2s)−1−ヒドロキシ−3−メチルブタン−2−イル]−7−メトキシ−4−オキソ−1,4−ジヒドロキノリン−3−カルボン酸またはその塩の使用 |
PL1992607T3 (pl) | 2006-03-06 | 2015-05-29 | Japan Tobacco Inc | Sposób wytwarzania związku 4-oksochinolinowego |
CN101437801B (zh) | 2006-03-06 | 2013-02-06 | 日本烟草产业株式会社 | 制备4-氧代喹啉化合物的方法 |
US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
WO2008010953A2 (en) | 2006-07-19 | 2008-01-24 | University Of Georgia Research Foundation, Inc. | Pyridinone diketo acids: inhibitors of hiv replication in combination therapy |
AU2007293774C1 (en) | 2006-09-07 | 2014-12-18 | Albert Einstein College Of Medicine, Inc. | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases |
MX2009002689A (es) | 2006-09-12 | 2009-03-26 | Gilead Sciences Inc | Proceso e intermediarios para preparar inhibidores de integrasa. |
EP2084160A1 (en) | 2006-10-18 | 2009-08-05 | Merck & Co., Inc. | Hiv integrase inhibitors |
ES2603617T3 (es) | 2007-02-23 | 2017-02-28 | Gilead Sciences, Inc. | Moduladores de propiedades farmacocinéticas de la terapéutica |
US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
WO2009006203A1 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
CN103480000A (zh) | 2007-06-29 | 2014-01-01 | 吉里德科学公司 | 治疗用组合物和方法 |
WO2009018350A1 (en) | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Pyrone analog compositions and methods |
AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
EA201200631A1 (ru) | 2007-11-16 | 2012-11-30 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
GB0803019D0 (en) | 2008-02-19 | 2008-03-26 | Btg Int Ltd | Fluorinated compounds |
US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US20100272811A1 (en) | 2008-07-23 | 2010-10-28 | Alkermes,Inc. | Complex of trospium and pharmaceutical compositions thereof |
EP2320909B8 (en) | 2008-07-25 | 2016-03-30 | VIIV Healthcare Company | Chemical compounds |
WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011816A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
PT2320908E (pt) | 2008-07-25 | 2014-03-06 | Shionogi & Co | Pró-fármacos de dolutegravir |
ES2964383T3 (es) | 2008-12-11 | 2024-04-05 | Viiv Healthcare Co | Procesos e intermedios para inhibidores de la integrasa del VIH de carbamoilpiridona |
MX2011006241A (es) | 2008-12-11 | 2011-06-28 | Shionogi & Co | Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios. |
TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
US8835461B2 (en) | 2009-03-26 | 2014-09-16 | Shionogi & Co., Ltd. | Substituted 3-hydroxy-4-pyridone derivative |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
PT2444400T (pt) | 2009-06-15 | 2018-06-06 | Shionogi & Co | Derivado de carbamoilpiridona policíclico substituído |
KR101280198B1 (ko) | 2009-09-02 | 2013-06-28 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
ES2688925T3 (es) | 2010-01-27 | 2018-11-07 | Viiv Healthcare Company | Tratamiento antiviral |
WO2011105590A1 (ja) | 2010-02-26 | 2011-09-01 | 日本たばこ産業株式会社 | 1,3,4,8-テトラヒドロ-2H-ピリド[1,2-a]ピラジン誘導体及びそのHIVインテグラーゼ阻害剤としての利用 |
TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
JP5806735B2 (ja) | 2010-07-02 | 2015-11-10 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv抗ウイルス化合物としての2−キノリニル−酢酸誘導体 |
US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
EP2595986A2 (en) | 2010-07-14 | 2013-05-29 | Addex Pharma SA | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
CN106083891B (zh) | 2010-08-05 | 2018-03-23 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的化合物的制造方法 |
SI2620436T1 (en) | 2010-09-24 | 2018-08-31 | Shionogi & Co., Ltd. | A prodrug substituted polycyclic carbamoyl pyridone derivative |
WO2012106534A2 (en) | 2011-02-02 | 2012-08-09 | The Regents Of The University Of California | Hiv integrase inhibitors |
AP2015008931A0 (en) | 2011-04-21 | 2015-12-31 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
US20140213553A1 (en) | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
US9206197B2 (en) | 2011-09-14 | 2015-12-08 | Mapi Pharma Ltd. | Amorphous form of dolutegravir |
US9200009B2 (en) | 2011-10-12 | 2015-12-01 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase inhibitory activity |
WO2013087581A1 (en) | 2011-12-12 | 2013-06-20 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines |
UY34750A (es) | 2012-04-20 | 2013-11-29 | Gilead Sciences Inc | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. |
WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
WO2014014933A1 (en) | 2012-07-20 | 2014-01-23 | Merck Sharp & Dohme Corp. | Hiv treatment with amido-substituted pyrimidinone derivatives |
EP2877469A4 (en) | 2012-07-25 | 2016-04-06 | Merck Sharp & Dohme | SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE |
US8877931B2 (en) | 2012-08-03 | 2014-11-04 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
WO2014074675A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
JP2016503030A (ja) | 2012-12-14 | 2016-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 医薬組成物 |
WO2014099586A1 (en) * | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
EP2934482A4 (en) | 2012-12-21 | 2016-07-20 | Merck Sharp & Dohme | ADMINISTRATIVE FORMULATIONS |
US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR102527797B1 (ko) | 2012-12-21 | 2023-05-03 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
US20140221380A1 (en) | 2012-12-27 | 2014-08-07 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR |
EP3008044B1 (en) | 2013-06-13 | 2018-11-21 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
NO2865735T3 (hr) * | 2013-07-12 | 2018-07-21 | ||
CA2916993C (en) * | 2013-07-12 | 2019-01-15 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
WO2015039348A1 (en) * | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
EA030695B1 (ru) | 2013-09-27 | 2018-09-28 | Мерк Шарп И Доум Корп. | Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич |
US20150146340A1 (en) | 2013-11-26 | 2015-05-28 | Qualcomm Incorporated | Multilayer ceramic capacitor including at least one slot |
WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
EP3096763B1 (en) | 2014-01-21 | 2019-12-25 | Laurus Labs Limited | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof |
-
2012
- 2012-03-29 NO NO15151831A patent/NO2865735T3/no unknown
-
2014
- 2014-07-11 ES ES14745053.0T patent/ES2647216T3/es active Active
- 2014-07-11 CA CA2918055A patent/CA2918055C/en active Active
- 2014-07-11 JP JP2016525820A patent/JP6411492B2/ja active Active
- 2014-07-11 EP EP14745053.0A patent/EP3019499B1/en active Active
- 2014-07-11 US US14/329,697 patent/US9458159B2/en active Active
- 2014-07-11 RS RS20171143A patent/RS56539B1/sr unknown
- 2014-07-11 SI SI201431750T patent/SI3252053T1/sl unknown
- 2014-07-11 LT LTEP14745053.0T patent/LT3019499T/lt unknown
- 2014-07-11 HU HUE14745053A patent/HUE037343T2/hu unknown
- 2014-07-11 DK DK14745053.0T patent/DK3019499T3/da active
- 2014-07-11 WO PCT/US2014/046415 patent/WO2015006733A1/en active Application Filing
- 2014-07-11 EP EP17177428.4A patent/EP3252053B1/en active Active
- 2014-07-11 PT PT147450530T patent/PT3019499T/pt unknown
- 2014-07-11 AU AU2014286995A patent/AU2014286995B2/en active Active
- 2014-07-11 PL PL14745053T patent/PL3019499T3/pl unknown
- 2014-07-11 SI SI201430410T patent/SI3019499T1/sl unknown
- 2014-07-11 ES ES17177428T patent/ES2856867T3/es active Active
-
2016
- 2016-09-06 US US15/257,528 patent/US20170128444A1/en not_active Abandoned
- 2016-10-17 HK HK18105921.3A patent/HK1246295A1/zh unknown
- 2016-10-17 HK HK16111945.5A patent/HK1223615A1/zh unknown
-
2017
- 2017-11-02 CY CY20171101152T patent/CY1119545T1/el unknown
- 2017-11-21 HR HRP20171807TT patent/HRP20171807T1/hr unknown
-
2018
- 2018-05-17 US US15/982,197 patent/US10456395B2/en active Active
- 2018-09-24 AU AU2018236701A patent/AU2018236701B2/en active Active
-
2019
- 2019-09-16 US US16/572,159 patent/US11213523B2/en active Active
-
2020
- 2020-04-03 AU AU2020202368A patent/AU2020202368A1/en not_active Abandoned
-
2021
- 2021-11-22 US US17/532,148 patent/US11883397B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171807T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova uporaba za liječenje hiv infekcija | |
HRP20171808T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova uporaba za liječenje hiv infekcija | |
JP2016525102A5 (hr) | ||
HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
HRP20180483T1 (hr) | Spoj kinolona | |
MD4754C1 (ro) | Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică | |
MA42230A (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
HRP20230274T1 (hr) | Kemijski spojevi | |
HRP20180081T1 (hr) | Fuzionirani triciklični heterociklični spojevi kao inhibitori hiv integraze | |
JP2017537949A5 (hr) | ||
IL207468A (en) | HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections | |
HRP20161379T1 (hr) | Inhibitori hepatitis c virusa | |
JP2016527217A5 (hr) | ||
GB0612423D0 (en) | Therapeutic agents | |
NZ610315A (en) | Antiviral condensed heterocyclic compounds | |
PH12014501804A1 (en) | Cycloalkane derivative | |
AR062503A1 (es) | Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor. | |
HRP20231369T1 (hr) | Inhibitori lsd1 i njihova medicinska upotreba | |
HRP20202051T1 (hr) | Aril supstituirani pirimidini za uporabu kod infekcije virusom influence | |
TN2015000293A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
MX354423B (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
MX2014009850A (es) | Spiro [2.4] heptanos para aplicaciones relacionadas con el tratamiento de infecciones de flaviviridae. | |
GEP20207070B (en) | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | |
WO2014193269A3 (ru) | Лекарственное средство на основе дииндолилметана и его применение для лечения гриппа и респираторных вирусных инфекций |